Marcelo Morais Barbosa

Marcelo Morais Barbosa

Auto-generated profile, based on publicly available information

Marcelo Morais Barbosa

Instituto Nacional do Câncer

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in Revista Brasileira de Cancerologia
Verified
Journal Article
Open access
PDF file
TMTainara Rodrigues Miranda
Tainara Rodrigues Miranda
MCMarie Nathalie Chenu
Marie Nathalie Chenu
CFCamila de Carvalho Figueiredo
Camila de Carvalho Figueiredo
MBMarcelo Morais Barbosa
Marcelo Morais Barbosa
PJPatricia Chaves de Freitas Campos Jucá
Patricia Chaves de Freitas Campos Jucá
Introduction: Breast sarcoma is a rare form of malignancy that arises from connective tissue, comprising less than 5% of all sarcomas. Undifferentiated pleomorphic sarcoma (UPS) of the breast is a rare and aggressive subtype of radiation-induced sarcoma that can occur in treated breast cancer patients. The diagnosis is challenging and often missed due to the low incidence, long latency period, unspecific imaging finding, and difficulties in clinical and histological detection. Case report: A 56-year-old woman was diagnosed with early-stage triple-negative breast cancer in 2013 and underwent breast-conserving therapy (BCT). After five years follow-up, she developed mastalgia and breast induration, and after mammography and ultrasound without suspicious lesions, a magnetic resonance imaging (MRI) was performed and showed a highly suggestive malignancy mass measuring 8.0 cm and invading the chest wall. The core biopsy revealed a spindle cells malignant tumor, negative for pan cytokeratin and most of immuno-histochemical markers, suggesting sarcoma, but requiring investigation of surgical specimen to exclude metaplastic carcinoma. She underwent Halsted radical mastectomy, full-thickness left anterior chest wall resection contemplating segments of the 4th and 5th ribs and reconstruction with synthetic mesh. The surgical specimen evidenced a UPS with clear margins. The patient had good postoperative recovery and remains in follow-up with the mastology team. Conclusion: This report shows that radiation-induced sarcomas of the breast can be difficult to diagnose, and how later treatment can demand a major surgery with higher morbidity. Prognosis may improve if detected early.

20 August 2026 in Clinical Breast Cancer
Verified
Journal Article
Closed access
MBMarcelo Morais Barbosa
Marcelo Morais Barbosa
MBMarcelo Adeodato Bello
Marcelo Adeodato Bello
CNCristina Moreira Do Nascimento
Cristina Moreira Do Nascimento
LTLuiz Claudio Santos Thuler
Luiz Claudio Santos Thuler
ABAnke Katharina Bergmann
Anke Katharina Bergmann
FLFernanda Janaína Cunha Labre
Fernanda Janaína Cunha Labre

26 February 2025 in Mastology
Verified
Journal Article
Open access
CFCarolina Batista Fernandes
Carolina Batista Fernandes
RVRoberto Vieira
Roberto Vieira
MBMarcelo Barbosa
Marcelo Barbosa
EVEmanuelle Narciso Alvarez Valente
Emanuelle Narciso Alvarez Valente
MBMarcelo Adeodato Bello
Marcelo Adeodato Bello
MCMarcio Aurélio Pereira de Castro
Marcio Aurélio Pereira de Castro
In 2020, there were approximately 2.3 million new cases of breast cancer worldwide. Breast-conserving surgery followed by adjuvant radiotherapy has replaced radical and modified radical mastectomy as the standard treatment for patients with early-stage breast cancer, with equivalent overall survival and disease-free survival rates. Oncoplastic techniques consist in removing the tumor from the breast and applying plastic surgery techniques for breast reconstruction. The use of oncoplastic techniques may increase the number of women who experience postoperative complications or who are recalled for biopsy. Complication rates of around 16% can be considered acceptable, with the most common immediate complications being delayed wound healing, fat necrosis, and infection, while late complications being fibrosis and breast asymmetry. The use of hyperbaric oxygen therapy (HBOT) appears as an alternative for the treatment of these conditions. The Undersea and Hyperbaric Medical Society recognizes 14 valid medical indications for HBOT. Among these, those that stand out with interest in mastology are: chronic wounds; compromised flaps and grafts; radiotoxicity and soft tissue infections. Although most of the evidence is the result of observational studies or is extrapolated from the use of HBOT in other areas, its use may contribute to better outcomes in patients undergoing surgical treatment for breast cancer.

26 June 2024 in Revista Brasileira de Cancerologia
Verified
Journal Article
Open access
PDF file
MBMarcelo Adeodato Bello
Marcelo Adeodato Bello
ABAnke Katharina Bergmann
Anke Katharina Bergmann
SASuzana Sales de Aguiar
Suzana Sales de Aguiar
MBMarcelo Morais Barbosa
Marcelo Morais Barbosa
EVEmanuelle Narciso Alvarez Valente
Emanuelle Narciso Alvarez Valente
LTLuiz Claudio Santos Thuler
Luiz Claudio Santos Thuler
Introdução: O câncer de mama (CM) é o mais comum entre as mulheres. A quimioterapia neoadjuvante (QTNEO) visa melhorar as condições cirúrgicas em pacientes com CM localmente avançado. Objetivo: Comparar as características demográficas, clínicas e de tratamento de mulheres submetidas à QTNEO para tratamento de CM de acordo com a linfadenectomia axilar (LA) ou biópsia de linfonodo sentinela (BLS) e analisar os fatores associados à indicação de BLS em um cenário da vida real. Método: Estudo de coorte retrospectivo em mulheres com CM e indicação de QTNEO. Foram obtidas variáveis demográficas, clínicas, tumorais e de tratamento. Foi realizada regressão logística simples e múltipla para avaliar os fatores independentes associados à indicação de BLS. Resultados: Foram incluídas 918 pacientes, das quais 17,5% foram submetidas à BLS e 11,4% à BLS seguida de LA. As mulheres em estádio III tiveram 95% menos probabilidade de serem submetidas à BLS (OR = 0,05; IC 95%: 0,01-0,17; p < 0,001) em comparação com aquelas no estádio I. As submetidas à mastectomia apresentaram 90% menor chance de realizar BLS do que aquelas com cirurgia conservadora (IC95%: 0,06-0,17; p < 0,001). Considerando as respostas da QTNEO, os casos sem resposta ou com progressão da doença apresentaram chance 55% menor de serem submetidos à BLS em comparação às que apresentaram resposta total (OR = 0,45; IC 95%: 0,24-0,82; p = 0,009). Conclusão: A BLS foi realizada em 29% das pacientes após QTNEO. Pacientes que apresentavam estágio clínico mais avançado da doença e pior resposta à QTNEO e as que foram submetidas a mastectomias tiveram menor probabilidade de serem submetidas à BLS.